CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Full story
CSL and Alentis Therapeutics have started an exclusive global partnership to develop and promote lixudebart. The drug targets rare kidney and liver diseases. Alentis will receive an initial payment of 355 million US dollars. They may earn up to 1.2 billion US dollars in commercial milestones, and global profits will be shared.
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become […]